Published in Clin Cancer Res on January 01, 1998
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol (2011) 2.43
Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut (2001) 2.08
Replication past O(6)-methylguanine by yeast and human DNA polymerase eta. Mol Cell Biol (2000) 1.95
Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res (2008) 1.94
Systems biology of cisplatin resistance: past, present and future. Cell Death Dis (2014) 1.74
Metallo-intercalators and metallo-insertors. Chem Commun (Camb) (2007) 1.70
Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci U S A (1999) 1.69
Replication errors: cha(lle)nging the genome. EMBO J (1998) 1.62
DNA mismatch-specific targeting and hypersensitivity of mismatch-repair-deficient cells to bulky rhodium(III) intercalators. Proc Natl Acad Sci U S A (2006) 1.48
Apoptosis and molecular targeting therapy in cancer. Biomed Res Int (2014) 1.47
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. Br J Cancer (2002) 1.45
The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci U S A (2003) 1.41
Different mutator phenotypes in Mlh1- versus Pms2-deficient mice. Proc Natl Acad Sci U S A (1999) 1.32
KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann Surg Oncol (2009) 1.26
Frequent truncating mutation of TFAM induces mitochondrial DNA depletion and apoptotic resistance in microsatellite-unstable colorectal cancer. Cancer Res (2011) 1.20
Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer (2009) 1.19
YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. Nucleic Acids Res (2004) 1.16
Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. Front Oncol (2012) 1.14
Human POLB gene is mutated in high percentage of colorectal tumors. J Biol Chem (2012) 1.12
Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines. Br J Cancer (2003) 1.12
DNA mismatch binding and antiproliferative activity of rhodium metalloinsertors. J Am Chem Soc (2009) 1.10
Genetic analysis of mouse embryonic stem cells bearing Msh3 and Msh2 single and compound mutations. Mol Cell Biol (2000) 1.08
Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection. Blood (2008) 1.04
Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br J Cancer (2004) 1.04
The expression of mismatched repair genes and their correlation with clinicopathological parameters and response to neo-adjuvant chemotherapy in breast cancer. Int Semin Surg Oncol (2007) 1.03
Selective cytotoxicity of rhodium metalloinsertors in mismatch repair-deficient cells. Biochemistry (2011) 1.01
HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of MutSα. Mol Cell (2014) 0.98
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol (2013) 0.96
Cell-selective biological activity of rhodium metalloinsertors correlates with subcellular localization. J Am Chem Soc (2012) 0.95
Suppression of annexin A11 in ovarian cancer: implications in chemoresistance. Neoplasia (2009) 0.94
The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis (2006) 0.94
Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore. Eur J Clin Pharmacol (2008) 0.94
Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacol Ther (2016) 0.93
Mechanisms of Cisplatin-Induced Apoptosis and of Cisplatin Sensitivity: Potential of BIN1 to Act as a Potent Predictor of Cisplatin Sensitivity in Gastric Cancer Treatment. Int J Surg Oncol (2012) 0.93
Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc Natl Acad Sci U S A (2000) 0.93
Analysis of colorectal cancer morphology in relation to sex, age, location, and family history. J Gastroenterol (2012) 0.91
The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell cycle control and apoptosis: implications for pathogenesis, progression and therapy of cancer. J Mol Histol (2006) 0.91
Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors? J Hematol Oncol (2015) 0.90
Expression of the hMLH1 and hMSH2 proteins in normal tissues: relationship to cancer predisposition in hereditary non-polyposis colon cancer. Virchows Arch (2004) 0.89
Construction and characterization of mismatch-containing circular DNA molecules competent for assessment of nick-directed human mismatch repair in vitro. Nucleic Acids Res (2002) 0.88
BNIP3 is essential for mediating 6-thioguanine- and 5-fluorouracil-induced autophagy following DNA mismatch repair processing. Cell Res (2010) 0.87
Melanoma resistance to photodynamic therapy: new insights. Biol Chem (2013) 0.86
Deoxyribonucleic acid damage induced by doxorubicin in peripheral blood mononuclear cells: possible roles for the stress response and the deoxyribonucleic acid repair process. Cell Stress Chaperones (2003) 0.86
Differential cellular responses to prolonged LDR-IR in MLH1-proficient and MLH1-deficient colorectal cancer HCT116 cells. Clin Cancer Res (2009) 0.85
Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer. Br J Cancer (2014) 0.85
Molecular signaling mechanisms of apoptosis in hereditary non-polyposis colorectal cancer. World J Gastrointest Pathophysiol (2012) 0.84
No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin. BMC Cancer (2005) 0.84
Clinicopathological analysis of colorectal cancer: a comparison between emergency and elective surgical cases. World J Surg Oncol (2013) 0.84
Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol (2016) 0.83
Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin. BMC Cancer (2010) 0.83
Microsatellite instability in colorectal cancer. Radiol Oncol (2011) 0.82
Biological effects of simple changes in functionality on rhodium metalloinsertors. Philos Trans A Math Phys Eng Sci (2013) 0.82
MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition. Br J Cancer (2009) 0.81
5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis (2006) 0.81
Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links. DNA Repair (Amst) (2015) 0.80
Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine. Int J Mol Sci (2015) 0.80
An inducible, isogenic cancer cell line system for targeting the state of mismatch repair deficiency. PLoS One (2013) 0.80
Lack of EGF receptor contributes to drug sensitivity of human germline cells. Br J Cancer (2005) 0.80
An unusual ligand coordination gives rise to a new family of rhodium metalloinsertors with improved selectivity and potency. J Am Chem Soc (2014) 0.80
Oncologic management of hereditary colorectal cancer. Clin Colon Rectal Surg (2012) 0.79
Mismatch repair protein expression in colorectal cancer. J Gastrointest Oncol (2013) 0.79
Why are upper tract urothelial carcinoma two different diseases? Transl Androl Urol (2016) 0.78
MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma. Oncotarget (2015) 0.78
Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines. J Vet Med Sci (2015) 0.78
A novel DNA damage response mediated by DNA mismatch repair in Caenorhabditis elegans: induction of programmed autophagic cell death in non-dividing cells. Genes Cancer (2015) 0.78
Ubiquitin-specific Peptidase 10 (USP10) Deubiquitinates and Stabilizes MutS Homolog 2 (MSH2) to Regulate Cellular Sensitivity to DNA Damage. J Biol Chem (2016) 0.78
hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases. Clin Exp Metastasis (2012) 0.78
Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2. Br J Cancer (2002) 0.78
Brostallicin (PNU-166196)--a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells. Br J Cancer (2003) 0.78
Leukemia cells are sensitized to temozolomide, carmustine and melphalan by the inhibition of O(6)-methylguanine-DNA methyltransferase. Oncol Lett (2015) 0.78
A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity. Curr Genomics (2016) 0.78
Evolutionarily conserved genetic interactions with budding and fission yeast MutS identify orthologous relationships in mismatch repair-deficient cancer cells. Genome Med (2014) 0.77
Targeting DNA Flap Endonuclease 1 to Impede Breast Cancer Progression. EBioMedicine (2016) 0.77
An adsorptive transfer technique coupled with brdicka reaction to reveal the importance of metallothionein in chemotherapy with platinum based cytostatics. Int J Mol Sci (2010) 0.77
Histone deacetylase 10 regulates DNA mismatch repair and may involve the deacetylation of MutS homolog 2. J Biol Chem (2015) 0.76
Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. Mod Pathol (2015) 0.76
Rapid Identification of Chemoresistance Mechanisms Using Yeast DNA Mismatch Repair Mutants. G3 (Bethesda) (2015) 0.76
Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines. Invest New Drugs (2004) 0.76
Molecular insight into thiopurine resistance: transcriptomic signature in lymphoblastoid cell lines. Genome Med (2015) 0.75
Drugging the Cancers Addicted to DNA Repair. J Natl Cancer Inst (2017) 0.75
Down-regulation of DNA mismatch repair enhances initiation and growth of neuroblastoma and brain tumour multicellular spheroids. PLoS One (2011) 0.75
Targeting DNA Mismatches with Rhodium Metalloinsertors. Inorganica Chim Acta (2016) 0.75
Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma. Int J Mol Sci (2017) 0.75
Molecular prognostic factors in rectal cancer treated by preoperative chemoradiotherapy. Oncol Lett (2010) 0.75
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecol Oncol (2016) 0.75
A Monofunctional Platinum Complex Coordinated to a Rhodium Metalloinsertor Selectively Binds Mismatched DNA in the Minor Groove. Inorg Chem (2015) 0.75
DNA damage regulation and its role in drug-related phenotypes in the malaria parasites. Sci Rep (2016) 0.75
Synchronous glioblastoma and medulloblastoma in a child with mismatch repair mutation. Childs Nerv Syst (2015) 0.75
Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06
The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res (1999) 2.50
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells (1990) 2.43
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol (1999) 2.29
Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer (1993) 2.10
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene (1994) 1.88
Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells. Eur J Cancer Clin Oncol (1989) 1.68
Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst (1997) 1.58
cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res (1988) 1.56
The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer (2005) 1.54
Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol (1993) 1.52
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res (1997) 1.50
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res (1997) 1.47
Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med (1982) 1.46
Circulating immunoglobulin complexes in Wegener's granulomatosis. Am J Med (1976) 1.43
Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol (1992) 1.39
Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res (1985) 1.30
Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res (1997) 1.29
Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol (2001) 1.28
Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun (1990) 1.27
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer (2001) 1.26
Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer (1994) 1.26
Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res (1983) 1.23
Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck (1992) 1.22
Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck (2000) 1.21
Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer (1991) 1.18
Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol (1993) 1.16
Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res (1987) 1.16
Totally implantable system for peritoneal access. J Clin Oncol (1984) 1.15
Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents. Oncogene (2001) 1.15
Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol (1987) 1.13
Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res (2000) 1.13
Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol (1994) 1.11
Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem (1990) 1.10
Role of metallothionein in carcinogenesis. Toxicol Appl Pharmacol (1994) 1.10
Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol (1999) 1.08
Defects in cell-mediated immunity during growth of a syngeneic simian virus-induced tumor. Int J Cancer (1975) 1.07
Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153. Br J Cancer (1996) 1.06
Biochemical characterization of the human arsenite-stimulated ATPase (hASNA-I). J Biol Chem (1998) 1.03
Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer (1999) 1.03
Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest (1990) 1.03
Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol (1990) 1.01
The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br J Cancer (1998) 1.00
Improved targeting of platinum chemotherapeutics. the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. Eur J Cancer (2004) 1.00
Cell interactions in adoptive immune rejection of a syngeneic tumor. Int J Cancer (1974) 0.99
Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res (1993) 0.98
Induction of the growth arrest and DNA damage-inducible gene GADD153 by cisplatin in vitro and in vivo. Br J Cancer (1994) 0.98
Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res (2001) 0.98
Yeast mutants as a model system for identification of determinants of chemosensitivity. Pharmacol Rev (2000) 0.97
Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chem Biol Interact (1988) 0.97
P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res (2001) 0.97
Thymidine and hypoxanthine requirements of normal and malignant human cells for protection against methotrexate cytotoxicity. Cancer Res (1981) 0.95
Success and relapse rate after treatment of cryptorchidism with intranasal LHRH. Acta Paediatr Scand (1985) 0.94
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol (2007) 0.94
Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int J Cancer (2001) 0.94
Thymidine requirements for the rescue of patients treated with high-dose methotrexate. Cancer Res (1980) 0.94
Methotrexate pharmacokinetics after intraarticular injection in patients with rheumatoid arthritis. Arthritis Rheum (1980) 0.93
Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. J Clin Oncol (1984) 0.93
Cellular immunity in mice with simian virus 40-induced mKSA tumors: comparison of three assays of tumor immunity. J Natl Cancer Inst (1974) 0.93
In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest (1993) 0.93
Molecular characteristics of Haemophilus influenzae causing invasive disease during the period of vaccination in Switzerland: analysis of strains isolated between 1986 and 1993. J Clin Microbiol (1996) 0.93
Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60. J Clin Oncol (1993) 0.92
Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res (1992) 0.92
Identification of genes differentially expressed in association with acquired cisplatin resistance. Br J Cancer (2000) 0.92
Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells. J Clin Invest (1995) 0.92
Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer (1997) 0.92
Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity. J Clin Oncol (1985) 0.92
Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer (1998) 0.91
A randomized crossover trial assessing patient preference for two different types of portable infusion-pump devices. Ann Oncol (1999) 0.91
Expression of the DNA mismatch repair proteins hMLH1 and hPMS2 in normal human tissues. Br J Cancer (1997) 0.91
Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br J Cancer (1994) 0.91
The cellular pharmacology of oxaliplatin resistance. Eur J Cancer (2002) 0.91
Modulation of drug sensitivity by dipyridamole in multidrug resistant tumor cells in vitro. Cancer Res (1990) 0.91
all-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells. Clin Cancer Res (1997) 0.90
A targeted supradose cisplatin chemoradiation protocol for advanced head and neck cancer. Am J Surg (1994) 0.90
High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol (1985) 0.90
Isolation of the ATP-binding human homolog of the arsA component of the bacterial arsenite transporter. Genomics (1996) 0.90
Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res (1991) 0.89
Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia. Ann Oncol (2001) 0.89
Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. Ann Oncol (2003) 0.89
Modulation of cisplatin cytotoxicity by permeabilization of the plasma membrane by digitonin in vitro. Biochem Pharmacol (1993) 0.89
Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells. Br J Cancer (2000) 0.89
Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion. J Clin Oncol (1985) 0.88
Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol (1995) 0.88
Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Anticancer Res (1989) 0.88
Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation. Cancer (1993) 0.88
Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. Int J Cancer (1993) 0.88
Pilot study of intra-arterial floxuridine, mitomycin and doxorubicin in combination with degradable starch microspheres to treat primary and metastatic tumors of the liver. Cancer Drug Deliv (1985) 0.87
Loss of DNA mismatch repair due to knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin. Int J Oncol (1997) 0.87